{
  "id": "d11e47e0b0dd523c",
  "title": "FDA approves Roche Lunsumio VELO\u2122 for subcutaneous use in relapsed or refractory follicular lymphoma",
  "description": "20251222T083000Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/22/tmt-newswire/globenewswire/fda-approves-roches-lunsumio-velo-for-subcutaneous-use-in-relapsed-or-refractory-follicular-lymphoma/2247761",
  "published_at": "20251222T083000Z",
  "fetched_at": "2025-12-23T00:22:44.609575+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/22/tmt-newswire/globenewswire/fda-approves-roches-lunsumio-velo-for-subcutaneous-use-in-relapsed-or-refractory-follicular-lymphoma/2247761",
    "url_mobile": "https://www.manilatimes.net/2025/12/22/tmt-newswire/globenewswire/fda-approves-roches-lunsumio-velo-for-subcutaneous-use-in-relapsed-or-refractory-follicular-lymphoma/2247761/amp",
    "title": "FDA approves Roche Lunsumio VELO\u2122 for subcutaneous use in relapsed or refractory follicular lymphoma",
    "seendate": "20251222T083000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/22/876413.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}